Table 1.
Clinical Characteristics of 15 Patients Studied by Array CGH.
Figure 1.
Genomic aberrations in pancreatic cancer.
A. Genome-wide frequency plot of pancreatic cancer by array CGH analysis. Line on the right of 0%-axis, gain; line on the left of 0%-axis, loss. B. Numbers of aberrations in pancreatic cancer. X, number of aberrations; Y, number of cases. C. Gains and losses (HDs) identified by GISTIC.
Table 2.
Genomic Gains and Losses in Pancreatic Cancer.
Figure 2.
Amplification of AKT2 and homozygous deletion of CDKN2C in pancreatic cancer.
A. amplification of AKT2. B. homozygous deletion of CDKN2C. Arrows indicate the position of AKT2 and CDKN2C.
Figure 3.
Homozygous deletion of APOBEC3A and APOBEC3B in pancreatic cancer.
Cycles represent the probes of APOBEC3A and APOBEC3B.
Table 3.
High Level Amplifications and Homozygous Deletions in Pancreatic Cancer.
Figure 4.
Validation of amplifications and homozygous deletions of candidate genes in independent pacreatic cancer tissues.
A. amplication of AKT2 and MCM7. B. homozygous deletion of CAMTA2 and PFN1. C. homozygous deletion of APOBEC3A and APOBEC3B. Ratio = (Copy number of candidate gene in tumor tissues)/(Copy number of candidate gene in commercial human genomic DNA).
Figure 5.
mRNA expression of candidate genes in pancreatic cancer as compared with that in morphologically normal operative margin tissues detected by using Real-time PCR.
A. Overexpression of AKT2 and MCM7. B. Underexpression of CAMTA2 and PFN1. C. Underexpression of APOBEC3A and APOBEC3B.
Table 4.
Pathways Enriched in Array CGH Data.
Figure 6.
Representative immunohistochemistry results of HMGA2 and PSCA in pancreatic cancer as compared with those in morphologically normal operative margin tissues.
A. Strong and negative expression of HMGA2. B. Strong and negative expression of PSCA.
Table 5.
Association between PSCA Expression and Clinicopathological Characteristics of the Pancreatic Cancer.
Table 6.
Association between HMGA2 Expression and Clinicopathological Characteristics of the Pancreatic Cancer.